Navigation Links
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
Date:9/20/2010

he evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics Inc., please visit www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the possibility that the acquisition of Penwest Pharmaceuticals is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceuti
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
2. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
3. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
5. Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
7. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
8. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
9. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
11. Access Pharmaceuticals Launches MuGard Product Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... , May 23, 2013  The need ... cancer treatment continuum was highlighted prominently at the ... Urological Association (AUA), in San Diego.  According to ... intensity focused ultrasound (HIFU) technology, the need for ... and for urologists to consider minimally invasive ablative ...
(Date:5/23/2013)... ANN ARBOR, Mich. , May 23, 2013  Every ... crucial flow of air to his lungs. April ... somehow the dire predictions weren,t true. "Quite a ... leaving the hospital alive," says April Gionfriddo ... we were desperate. Anything that would work, we would take ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... - Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company ... from two Phase III clinical trials for ... moderately severe,seasonal allergic rhinitis, commonly known as ... levels in both placebo and,PreHistin-treated patient groups, ...
... cell lung cancer -, LOS ANGELES, July 09, ... positive Phase III clinical,data published in the July ... that low expression of the biomarker,Excision-Repair Cross-Complementing 1 ... cancer (NSCLC) predicts for,sensitivity to cisplatin-based chemotherapy. ERCC-1 ...
Cached Medicine Technology:Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
(Date:5/23/2013)... York (PRWEB) May 23, 2013 ... C.R. Bard, Inc., continue to move forward in a ... District of West Virginia, Bernstein Liebhard LLP reports. ... denied a request by C.R. Bard to seal emails ... trade secrets and other confidential, proprietary information about its ...
(Date:5/23/2013)... Spring and summer have always been motivation ... Jackson , the city between Memphis and Nashville? In the ... wellness centers has transformed the growing area into one of ... any city of vibrant, young professionals you are going to ... Kim White, owner of The Fight Shop, one of the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Parker Waichman ... rights of victims injured by defective medical devices and ... Matthew J. McCauley has been appointed Co-Lead Counsel in ... IUD Products Liability Litigation (Case 7:13-md-02434-CS). The Order, which ... Liaison Counsel are to submit their proposal for the ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A shortage of ... health departments across the United States to contain the ... report. The drug, isoniazid (INH), was first used ... to be the core of any first-line treatment for ... to nine months, according to the U.S. Centers for ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... Pa., Aug. 4 On July 27, 2009 Aetna Inc., one ... drop in profit for Q 2 2009. , , ... claim intensity, such as services rendered in a higher cost setting ... for emergency room, ambulatory, laboratory and preventive services." "We are ...
... Expert warns that consequences of osteoporosis go far beyond weak bones, ... a hip have nearly a 25 percent chance of dying in ... five-year death rate for those who have a spinal fracture is ... Aug. 4 issue of the Canadian Medical Association Journal . ...
... , , , , ... of the school year , , ROSEMONT, Ill., Aug. ... to school in the weeks ahead. Shopping for school supplies and ... classes is brewing for both parents and students, mixed with the questions ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , , ... awareness and research for musculoskeletal diseases , , ... America,s Orthopaedic Services Act of 2009 (AAOS Act), S. 1548, was introduced ... Burr (R-NC). , , This introduction, the first ...
... , , HARRISBURG, Pa., Aug. ... across the state on the new Integrated Care Initiative, an effort ... and Medicaid issues. , , The new health ... create a single source for consumers to work with both agencies, ...
Cached Medicine News:Health News:Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 2Health News:With a Broken Hip Comes Higher Risk for Dying 2Health News:With a Broken Hip Comes Higher Risk for Dying 3Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 2Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 3Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 4Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Access to America's Orthopaedic Services Act of 2009 Introduced in the Senate 2Health News:Access to America's Orthopaedic Services Act of 2009 Introduced in the Senate 3Health News:Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 2
... With BareWire technology, the wire crosses ... and delivery catheter. All other actions, including ... stent placement then occur over the wire., ... can break off during a carotid stenting ...
... Designed to fully integrate ... multidisciplinary clinical laboratory working under ... suite uses five core modules ... management and create an environment ...
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... DSL's unique DHEA-S-7kits feature ... targeted against the C-7 ... molecule, with no cross-reactivity ... Saliva RIA has been ...
Medicine Products: